SVR

Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis-C Virus (HCV)

...eatment. HCV infection is considered cured when a svr of undetectable viral load is maintained more than...ered at the outset of SOC therapy provided a 77.8% svr in HCV-infected patients. In patients who previou...sly failed SOC, DFPP treatment provided an average svr of 71.4% versus the 51% previously referenced in T...

AGA Institute presents cutting-edge research during DDW

...rrence. I. Lowy et al. (2:30 p.m.)* Effectiveness of the Third Eye Retroscope for Detecting Polyps in the Right Colon. J.D. Waye et al. (2:45 p.m.) svr Results of PROVE3, a Phase 2b Clinical Trial Assessing Safety and Efficacy of Telaprevir in Hepatitis C Genotype-1-Infected Patients with Prior Non-re...

New treatment option for patients with chronic hepatitis C

...o have failed to respond to treatment with peg-IFN and RBV can be successfully retreated with daily CIFN and RBV," the authors conclude. "The greatest svr rate during retreatment in the present study was observed in F0-F3 patients who had a partial virologic response during their prior course of treatmen...

2-day results predict ultimate response to therapy in chronic hepatitis C

...African Americans have consistently lower rates of svr to interferon-based therapy, compared to Caucasian...c measurement was a reliable predictor of ultimate svr rates. After 28 days of treatment, 22 percent of ..., "[this study] demonstrates that the low rates of svr in African American patients in response to IFN-ba...

Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology

...defined as undetectable serum HCV RNA at week 4 of combination therapy, and svr were significantly higher in patients given the triple therapy compared wit...zoxanide plus peginterferon alfa-2a had intermediate rates of RVR (54%) and svr (61%). Adverse events were similar across treatment groups except for a hig...

Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients

...a 48-week boceprevir regimen achieved a 75 percent svr rate in patients who received 4 weeks of PEGINTRON... This represents a near doubling of the 38 percent svr rate for patients in the control group receiving 4...) In a 28-week boceprevir P/R lead-in regimen, the svr rate was 56 percent (n=103). Importantly, for pati...

PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine

...rated that there were differences in predictors of svr between the two patient populations.(1) The result...eatment strategies in order to improve the rate of svr among Latino patients infected with HCV genotype 1...4 percent (90/269) of the Latino patients achieved svr when treated with PEGASYS plus COPEGUS.(1) In comp...

Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C

...to 48 weeks of treatment, 55 percent achieved SVR. As with adult patients, svr in pediatric patients with HCV genotype 2 or 3 LVL was much higher than in those with genotype 1; the svr rate was 96 percent in children with HCV genotype 2 or 3 LVL. In t...

How to increase the chances of remaining virus free Pakistani patients with HCV?

...t virus clearance until six months after completing the treatment. This is called Sustained Virological Response (SVR). It is difficult to predict the svr in patients receiving ongoing therapy. A team of doctors, led by Dr. Bader Faiyaz Zuberi at Dow University of Health Sciences, Pakistan, conducted...

Treating patients with psychiatric disorders for hepatitis C

...ychotic symptoms and demonstrates that neither diagnosis adversely affected svr or outcome. Instead, the study adds to the growing body of evidence that sh...efer et. als study means that the conclusion that there is no difference in svr between controls and patients with mental health diagnosis is stronger than...

SVR in Medical Technology

Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients

48-week investigational regimen yielded nearly double SVR rate compared to standard of care Update on next-generation HCV protease inhibitor SCH 900518 presented at EASL annual meeting COPENHAGEN, Denmark, April 23 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) toda...

Pegintron(TM) Plus Weight-Based Rebetol(R) Resulted in Higher SVR Than Flat Dosing; Low Relapse Rates in Patients With Chronic Hepatitis C

FDA Approves Label Revisions Recommending New Weight-Based Dosing Regimen KENILWORTH, N.J., March 27 /PRNewswire/ -- Schering-Plough Corporation (NYSE: SGP ) today reported that the U.S. Food and Drug Administration (FDA) has approved label revisions for PEGINTRON(TM) (peginterferon alfa-2b) a...

Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting

... treatment duration or a reduced PEGINTRON dose on svr and relapse rates among treatment-naive G2/3 patie...non-inferiority between arms A and B and A and C. svr rates overall were (A) 66.5 percent (153/230), (B)... (EASL); April 22-26, Copenhagen, Denmark. 3. svr is defined as achievement of undetectable HCV-RNA ...

Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen

... The companies also plan to explore the innovative DAA combination therapy in "treatment-experienced" patients with HCV, or those who did not achieve svr with a previous interferon-based treatment. Other Clinical Studies with R7227 and R7128 In addition to clinical studies of combination DAA...

Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C

...ine stratification factors, showed a difference in svr rates of -1.8% (95% CI -8.1%, 4.5%, p=0.0008 for n...CHIEVE 2/3 : 79.8% (249/312) of patients achieved svr in the 900-mcg albinterferon alfa-2b treatment gro...ine stratification factors, showed a difference in svr rates of -4.8% (95% CI -10.7%, 1.1%, p=0.0086 for ...

FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C

...week 12, those infected with HCV genotype 1 had an svr rate of 48 percent (245/507), with a range of resp...A undetectable at treatment week 12 had an overall svr of 70 percent (196/281), with a range of responses...NA at week 12 or 24 are highly unlikely to achieve svr and discontinuation of therapy should be considere...

Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C

...iority to peginterferon alfa-2a, with 48.2% (213/442) of patients achieving svr in the 900-mcg albinterferon alfa-2b treatment group, vs. 51.0% (225/441) i...ich is adjusted for baseline stratification factors, showed a difference in svr rates of -1.8% (95% CI -8.1%, 4.5%, p=0.0008 for non-inferiority). ...

Pharmasset Reports Fiscal Year End 2008 Financial Results

...nt with clevudine or tenofovir with a combination of the two. In this study patients will be treated for two years, followed by a determination of the svr rates. Pharmasset is currently enrolling two registration trials worldwide (studies 305 and 306) and as a result of unforeseen regulatory dela...

Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C

... This represents a near doubling of the 38 percent svr 24 rate for patients in the control group receivin... In a 28-week boceprevir P/R lead-in regimen, the svr 24 rate was 56 percent. Importantly, for patients...) in plasma after 4 weeks of boceprevir treatment, svr was 94 percent in the 48 week regimen and 82 perce...

Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients

... rates with 28 weeks of therapy and nearly doubled svr with 48 weeks of therapy compared to current stand...Meeting.(1) In a 48-week boceprevir regimen, the svr rate was 74 percent at 12 weeks after the end of t...P/R lead-in). In a 28-week boceprevir regimen, the svr rate was 56 percent at 24 weeks after the end of t...

SVR in Medical Products

SVR Surgical Ventricular Restoration System

Description:... The svr System eliminates the guesswork of Ventricular Res...zing ventricular size, shape and orientation The svr System is a comprehensive surgical therapy for pat...ricle to its optimal elliptical shape by using the svr System and Mannequin results in significantly impr...
Company:Chase Medical

SVR in Biological Technology

Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights

...expectations regarding the amount of cost-savings associated with the reduction in force and facilities move; (vi) the ability to achieve EVR, RVR and svr in the Phase II study; (vii) the expectation to begin patient dosing in the ANA598 Phase II study within the next several weeks; and (viii) plans to e...

Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once-Daily INFERGEN(R) with Ribavirin in Hepatitis C Virus Treatment Failures

...ment with INFERGEN in combination with RBV yielded svr rates as high as 31.6 % in interferon-sensitive pa...responders to PEG-IFN/RBV therapy can help predict svr rates in this difficult-to-treat group of patients. All patients attaining svr demonstrated > 2-log drop at Week 12 of INFERGE...

Aethlon Medical Announces Data Supported Strategy to Increase Hepatitis-C (HCV) Cure Rates

...irological response (SVR) from the current interferon-ribavirin standard of care and other candidate therapies. HCV infection is considered cured when svr extends beyond six months. At present, less than 50% of HCV patients respond to interferon-ribavirin therapy. Additionally, there is a direct correla...

Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C

...iority to peginterferon alfa-2a, with 79.8% (249/312) of patients achieving svr in the 900-mcg albinterferon alfa-2b treatment group, vs. 84.8% (263/310) i... alfa-2a treatment group (p=0.0086 for non-inferiority). By region, svr rates were North America: 82.5% (85/103) for 900-mcg albinterferon...

Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at AASLD 2008

... Findings Include 80% svr Rate with Nitazoxanide-Based Combination Therapy a...dition of peginterferon for 36 weeks experienced a svr 24 weeks after the end of treatment compared to 50...notype 1, and 100% (n=1) of HCV genotype 2, had an svr with undetectable virus at 24 weeks following end ...

Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders

...are needed to provide additional information about its potential to improve svr rates and possibly shorten the treatment duration for genotype 2 or 3 HCV p...imen. In Cohort 4, patients with HCV genotype 2 or 3 who did not achieve an svr with previous interferon-based therapy were administered R7128 1500mg BID i...

SVR in Biological Dictionary

Code

...es. ... Code Database. Codes for all games. svr 2009 Section. Everything svr 2009. Code -X.ws Blog ... Code -X.ws forums. svr 2009 Codes . View our huge SvR09 code index! .....